Here we reported for the first time a synergistic interaction of givinostat with trametinib, an approved MAPK inhibitor [65], and with venetoclax, an approved BCL-2 inhibitor [66], in CRLF2r BCP-ALL, a subgroup for which givinostat had previously proven to be an interesting candidate [27]. Here, BCL2 is linked to acute lymphoblastic leukemia.